ImmunoGen Inc (IMGN) Fundamental Analysis & Valuation

NASDAQ:IMGN • US45253H1014

Current stock price

31.23 USD
0 (0%)
At close:
31.24 USD
+0.01 (+0.03%)
After Hours:

This IMGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. IMGN Profitability Analysis

1.1 Basic Checks

  • IMGN had negative earnings in the past year.
  • IMGN had a negative operating cash flow in the past year.
IMGN Yearly Net Income VS EBIT VS OCF VS FCFIMGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

  • IMGN's Return On Assets of -8.94% is amongst the best of the industry. IMGN outperforms 89.06% of its industry peers.
  • The Return On Equity of IMGN (-13.09%) is better than 89.06% of its industry peers.
Industry RankSector Rank
ROA -8.94%
ROE -13.09%
ROIC N/A
ROA(3y)-34.29%
ROA(5y)-40.85%
ROE(3y)-78.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMGN Yearly ROA, ROE, ROICIMGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K -1.5K

1.3 Margins

  • IMGN has a better Gross Margin (98.61%) than 98.32% of its industry peers.
  • IMGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMGN Yearly Profit, Operating, Gross MarginsIMGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. IMGN Health Analysis

2.1 Basic Checks

  • IMGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, IMGN has more shares outstanding
  • IMGN has a worse debt/assets ratio than last year.
IMGN Yearly Shares OutstandingIMGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M
IMGN Yearly Total Debt VS Total AssetsIMGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 18.14 indicates that IMGN is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of IMGN (18.14) is better than 90.91% of its industry peers.
  • IMGN has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
  • IMGN has a Debt to Equity ratio of 0.16. This is in the lower half of the industry: IMGN underperforms 68.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z 18.14
ROIC/WACCN/A
WACC11.02%
IMGN Yearly LT Debt VS Equity VS FCFIMGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M -200M 300M

2.3 Liquidity

  • A Current Ratio of 5.69 indicates that IMGN has no problem at all paying its short term obligations.
  • IMGN has a Current ratio (5.69) which is comparable to the rest of the industry.
  • A Quick Ratio of 5.65 indicates that IMGN has no problem at all paying its short term obligations.
  • IMGN's Quick ratio of 5.65 is in line compared to the rest of the industry. IMGN outperforms 56.57% of its industry peers.
Industry RankSector Rank
Current Ratio 5.69
Quick Ratio 5.65
IMGN Yearly Current Assets VS Current LiabilitesIMGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. IMGN Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 62.20% over the past year.
  • Looking at the last year, IMGN shows a very strong growth in Revenue. The Revenue has grown by 200.63%.
  • The Revenue has been decreasing by -1.17% on average over the past years.
EPS 1Y (TTM)62.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%132.26%
Revenue 1Y (TTM)200.63%
Revenue growth 3Y9.75%
Revenue growth 5Y-1.17%
Sales Q2Q%636.36%

3.2 Future

  • The Earnings Per Share is expected to grow by 32.99% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 69.78% on average over the next years. This is a very strong growth
EPS Next Y108.78%
EPS Next 2Y56.06%
EPS Next 3Y44.14%
EPS Next 5Y32.99%
Revenue Next Year344.16%
Revenue Next 2Y154.65%
Revenue Next 3Y109.41%
Revenue Next 5Y69.78%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IMGN Yearly Revenue VS EstimatesIMGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B
IMGN Yearly EPS VS EstimatesIMGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

3

4. IMGN Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IMGN. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 81.49, which means the current valuation is very expensive for IMGN.
  • IMGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. IMGN is cheaper than 93.94% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of IMGN to the average of the S&P500 Index (22.62), we can say IMGN is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 81.49
IMGN Price Earnings VS Forward Price EarningsIMGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMGN Per share dataIMGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as IMGN's earnings are expected to grow with 44.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y56.06%
EPS Next 3Y44.14%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IMGN Dividend Analysis

5.1 Amount

  • No dividends for IMGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

IMGN Fundamentals: All Metrics, Ratios and Statistics

ImmunoGen Inc

NASDAQ:IMGN (2/9/2024, 8:00:02 PM)

After market: 31.24 +0.01 (+0.03%)

31.23

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-09
Earnings (Next)04-26
Inst Owners0.16%
Inst Owner Change0%
Ins Owners0.43%
Ins Owner Change0%
Market Cap8.72B
Revenue(TTM)287.70M
Net Income(TTM)-73.50M
Analysts70.53
Price Target31.69 (1.47%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)102.82%
Min EPS beat(2)85.91%
Max EPS beat(2)119.72%
EPS beat(4)4
Avg EPS beat(4)66.67%
Min EPS beat(4)23.99%
Max EPS beat(4)119.72%
EPS beat(8)6
Avg EPS beat(8)47.51%
EPS beat(12)10
Avg EPS beat(12)59.04%
EPS beat(16)13
Avg EPS beat(16)56.88%
Revenue beat(2)2
Avg Revenue beat(2)36.59%
Min Revenue beat(2)4.48%
Max Revenue beat(2)68.71%
Revenue beat(4)4
Avg Revenue beat(4)86.57%
Min Revenue beat(4)4.48%
Max Revenue beat(4)138.97%
Revenue beat(8)7
Avg Revenue beat(8)54.29%
Revenue beat(12)8
Avg Revenue beat(12)38.51%
Revenue beat(16)11
Avg Revenue beat(16)32.28%
PT rev (1m)0.02%
PT rev (3m)34.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.27%
EPS NY rev (1m)6.14%
EPS NY rev (3m)223.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.12%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)7.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 81.49
P/S 30.32
P/FCF N/A
P/OCF N/A
P/B 15.53
P/tB 15.53
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)0.38
Fwd EY1.23%
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS1.03
BVpS2.01
TBVpS2.01
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -8.94%
ROE -13.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.61%
FCFM N/A
ROA(3y)-34.29%
ROA(5y)-40.85%
ROE(3y)-78.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 109.3%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.69
Quick Ratio 5.65
Altman-Z 18.14
F-Score4
WACC11.02%
ROIC/WACCN/A
Cap/Depr(3y)63.67%
Cap/Depr(5y)66.52%
Cap/Sales(3y)1.33%
Cap/Sales(5y)3.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)62.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%132.26%
EPS Next Y108.78%
EPS Next 2Y56.06%
EPS Next 3Y44.14%
EPS Next 5Y32.99%
Revenue 1Y (TTM)200.63%
Revenue growth 3Y9.75%
Revenue growth 5Y-1.17%
Sales Q2Q%636.36%
Revenue Next Year344.16%
Revenue Next 2Y154.65%
Revenue Next 3Y109.41%
Revenue Next 5Y69.78%
EBIT growth 1Y59.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year44.66%
EBIT Next 3Y43.02%
EBIT Next 5Y35.85%
FCF growth 1Y-71.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-72.08%
OCF growth 3YN/A
OCF growth 5YN/A

ImmunoGen Inc / IMGN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ImmunoGen Inc?

ChartMill assigns a fundamental rating of 3 / 10 to IMGN.


What is the valuation status of ImmunoGen Inc (IMGN) stock?

ChartMill assigns a valuation rating of 3 / 10 to ImmunoGen Inc (IMGN). This can be considered as Overvalued.


How profitable is ImmunoGen Inc (IMGN) stock?

ImmunoGen Inc (IMGN) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for IMGN stock?

The Earnings per Share (EPS) of ImmunoGen Inc (IMGN) is expected to grow by 108.78% in the next year.